Acute chest pain (ACP) is a common and challenging presentation in clinical practice, often signifying severe conditions such as acute coronary syndrome (ACS). However, the differential diagnosis is broad, encompassing less critical conditions, making its evaluation complex and crucial.
Initial evaluation should include a comprehensive history, physical examination, and initial diagnostic tests. The history should focus on pain characteristics and associated symptoms. Risk factors for ACS should be identified. Physical examination, although often normal in ACS, can reveal important clues in other conditions. Initial diagnostic tests should include an electrocardiogram (ECG) and cardiac biomarkers.
Clinical decision rules like the HEART score can aid risk stratification and guide management. The HEART score incorporates history, ECG, age, risk factors, and troponin level, categorizing patients into low, intermediate, and high-risk groups. It has demonstrated high sensitivity and specificity in predicting major adverse cardiac events.
For patients with inconclusive initial evaluation, advanced diagnostic tests may be necessary. These include stress testing, coronary computed tomography angiography (CCTA), and invasive coronary angiography. The choice of test depends on the patient's pretest probability of ACS, risk stratification, and local resources.
Management strategies depend on the underlying cause. ACS requires urgent revascularization and medical therapy. Other conditions may need specific treatments or reassurance. All patients should receive risk factor modification and follow-up arrangements.
Evaluating and managing ACP requires a systematic and comprehensive approach. Clinical decision rules can aid in this process. Advanced diagnostic tests may be necessary in certain scenarios. Ultimately, the goal is to accurately diagnose the underlying cause and initiate appropriate management, while minimizing unnecessary investigations and potential harm.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation